The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor

✍ Scribed by Atreya Dash; Brett S. Carver; Jason Stasi; Dean F. Bajorin; Robert J. Motzer; George J. Bosl; Joel Sheinfeld

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 111 KB
• Volume: 112
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.23233

✦ Synopsis

Abstract

BACKGROUND

The initial management of patients with clinical stage IS (cIS) nonseminomatous germ cell tumor (NSGCT) has evolved from primary retroperitoneal lymph node dissection (RPLND) to induction chemotherapy. The objectives of the current study were to determine the clinical outcome, patterns of relapse, and incidence of teratoma in the retroperitoneum for men with cIS NSGCT.

METHODS

Between 1988 and 2004, 24 patients with cIS stage NSGCT were evaluated and treated at Memorial Sloan‐Kettering Cancer Center. Clinical and pathologic data were obtained from the institutional prospective database. Seven patients underwent primary RPLND, and 17 patients received induction chemotherapy as initial management. Clinical outcomes, patterns of relapse, and pathologic findings were reported.

RESULTS

Six of the 7 patients who underwent primary RPLND had viable germ cell tumor (GCT) present. Four of those patients did not receive adjuvant chemotherapy, and all experienced systemic relapse. Of the 17 patients who received induction chemotherapy, 3 patients underwent elective postchemotherapy RPLND (PC‐RPLND), and 14 patients were followed expectantly. Four patients who were followed expectantly relapsed in the retroperitoneum and underwent PC‐RPLND. Of the 7 patients who underwent PC‐RPLND, 1 patient had fibrosis (14%), but 6 patients (86%) had teratoma, including 1 patient who also had a viable GCT in the retroperitoneum. Overall, the incidence of teratoma or viable GCT in the retroperitoneum after chemotherapy was 43% (6 of 14 patients). At a median follow‐up of 35 months, 23 men remained alive, and 1 man had died of disease.

CONCLUSIONS

The current data suggest that patients with cIS stage NSGCT will benefit from adjuvant PC‐RPLND. Cancer 2008. © 2008 American Cancer Society.